ARTICLE | Company News
Merck KGaA, Ono Pharmaceutical deal
June 23, 2014 7:00 AM UTC
Merck is returning rights to Ono for ceralifimod ( ONO-4641), a sphingosine 1-phosphate (S1P) receptor agonist in development for multiple sclerosis (MS). Merck’s Merck Serono S.A. unit has exclusiv...